Clinical Trial Update: GC012F in Patients With Autoimmune Diseases [EARLY_Phase 1]

View source ↗

Summary

This early-phase trial update reports on GC012F being studied for autoimmune diseases (systemic sclerosis and idiopathic inflammatory myopathy), with the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Inflammatory Myopathy
• Systemic Sclerosis

Drugs mentioned

• GC012F

Snippet

Sponsor: Qiong Fu | Conditions: Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM) | EARLY_Phase 1 | Status: NOT_YET_RECRUITING